Hear more from a patient who’s 
experienced shingles suffering

Video player requires JavaScript enabled. You can download this video here: https://videos.gskinternet.com/pharma/erpitaszostiras.cy/en-cy/EDIT_25 CUT VERSION_10.mp4
 

 

“Shingles? I thought

I was too young.
The pain made me want
to rip my skin off.”*

Patient portrayal.

*Inspired by real patient stories. Shingles symptoms may vary among patients.1

Are you at risk of shingles?

90% of people over 50

carry the virus that causes shingles2†

At 50 years

your risk of shingles sharply increases1,3

Even if you're healthy,

the virus that causes shingles can reactivate at any time1

Not everyone at risk will develop shingles.1

Don’t underestimate shingles 

Shingles pain can be excruciating. It can feel like burning, stabbing or shock-like. The pain can make even simple daily tasks challenging.1,4

image
image
image
image

Don’t let shingles put your life on hold

imgalt mobileimage

$noteContent

Shingles prevention options

LEARN MORE HERE
imgalt2 mobileimage2

$noteContent

Act now – start the discussion with your doctor

download discussion guide

All images across the webpage are patient portrayals.

If you experience any side effects while taking a medicinal product, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Adverse events should be reported directly to the Cypriot Ministry of Health on the Yellowcard website: Κίτρινη Κάρτα - Υπουργείο Υγείας

Disease awareness information provided by GSK intended for members of the public in Cyprus only. This information is not intended to be a substitute for professional medical advice. Talk to your doctor for more information about shingles.

References
  1. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1–30.
  2. Bollaerts K, Riera-Montes M, Heininger U, et al. A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data. Epidemiol Infect. 2017;145:2666–2677.
  3. Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63(33):729–731.
  4. Weinke T, Edte A, Schmitt S, Lukas K. Impact of herpes zoster and post-herpetic neuralgia on patients’ quality of life: a patient-reported outcomes survey. Z Gesundh Wiss. 2010;18:367–374.